Day One Biopharmaceuticals, Inc.DAWNNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank65
3Y CAGR+18.8%
5Y CAGR-13.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+18.8%/yr
Quarterly compound
5Y CAGR
-13.9%/yr
Recent acceleration
Percentile
P65
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 30.33% |
| Q3 2025 | -13.08% |
| Q2 2025 | -8.76% |
| Q1 2025 | -35.92% |
| Q4 2024 | 84.20% |
| Q3 2024 | -63.56% |
| Q2 2024 | 129.06% |
| Q1 2024 | 7.66% |
| Q4 2023 | 12.62% |
| Q3 2023 | 3.05% |
| Q2 2023 | 15.65% |
| Q1 2023 | 6.95% |
| Q4 2022 | 18.08% |
| Q3 2022 | -2.33% |
| Q2 2022 | 50.37% |
| Q1 2022 | 34.09% |
| Q4 2021 | 13.61% |
| Q3 2021 | -0.66% |
| Q2 2021 | -21.52% |
| Q1 2021 | 203.29% |
| Q4 2020 | 64.17% |
| Q3 2020 | 76.55% |
| Q2 2020 | 49.53% |
| Q1 2020 | 0.00% |